Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

ABSTRACT:

Introduction

Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamide and an accelerated prednisone taper.

Methods

Patients were included in this retrospective study if they had newly diagnosed or relapsing ANCA vasculitis with a Birmingham Vasculitis Activity Score for Wegener Granulomatosis (BVAS-WG) ≥3 and received a standardized remission induction regimen. The primary outcome was complete remission, defined as a BVAS-WG of 0 and a prednisone dose of ≤7.5 mg/d.

Results

We identified 129 patients who met the inclusion criter

SUBMITTER: Cortazar FB 

PROVIDER: S-EPMC5932132 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature